PT-141 – 10 mg

PT-141, commonly known as bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). Its activity across melanocortin receptor subtypes makes it a useful compound for research into receptor pharmacology, melanocortin signaling, and related cellular pathways. The 10 mg presentation is intended for qualified research environments conducting controlled investigations into melanocortin receptor activity, peptide structure, receptor interactions, and associated signaling mechanisms.

Key Features

10 mg research-grade PT-141 PT-141 / Bremelanotide Synthetic cyclic melanocortin peptide α-MSH analogue Relevant to melanocortin receptor research Suitable for receptor-binding and signaling studies Intended for controlled in-vitro and preclinical research Appropriate for peptide characterization and analytical workflows Batch-level analytical documentation may be provided for applicable lots Research Focus Bremelanotide has been characterized as a melanocortin receptor agonist with activity across several receptor subtypes, including MC1R, MC3R, MC4R, and MC5R. This receptor profile makes PT-141 relevant to laboratory investigations into melanocortin pharmacology, receptor selectivity, and downstream cellular signaling.

Important Notice

This product is supplied strictly for research and laboratory use. It is not intended for human or veterinary use, self-administration, consumption, sexual-performance enhancement, diagnosis, treatment, or prevention of disease. Bremelanotide is also available as an FDA-approved prescription medicine in a specific pharmaceutical formulation; this research material should not be represented as equivalent to that approved product.